Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the fourth quarter of 2023. Aerovate Therapeutics reported earnings per share of -74 cents. This was below the analyst estimate for EPS of ...
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might Be ...
STRO stock results show that Sutro Biopharma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might Be This ...
The former president is worth $6.4 billion based on a new Bloomberg estimate after a merger involving his media company thanks to a jump in the stock price of Digital World Acquisition.
In this context, as architects and designers have moved away from symmetrical, rigid, and parallel mirror patterns, Alcon ...